[Federal Register Volume 83, Number 176 (Tuesday, September 11, 2018)]
[Notices]
[Pages 45947-45948]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-19604]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: 
Photoactivatable Liposomal Nanoparticle for the Delivery of an 
Immunotherapeutic or Immunotherapeutic-Enabling Agent

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the Patents and Patent Applications listed in 
the Supplementary Information section of this notice to Nano Red LLC 
(``Nano Red'') located in Milwaukee, Wisconsin.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before September 26, 2018 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Jasmine Yang, Sr. Licensing and Patenting 
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM 
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville, 
MD 20850-9702 Telephone: (240) 276-5530; Facsimile: (240) 276-5504 
Email: <a href="/cdn-cgi/l/email-protection#630902100e0a0d064d1a020d04230d0a0b4d040c15"><span class="__cf_email__" data-cfemail="375d56445a5e5952194e56595077595e5f19505841">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: 

Intellectual Property

1. U.S. Provisional Patent Application (Application No. 61/845,861) 
filed July 12, 2013, HHS Reference No.: E-482-2013/0-US-01
2. PCT Application (Application No. PCT/US2014/045922) filed July 
09, 2014, HHS Reference No.: E-482-2013/0-PCT-02
3. Canada Patent Application (Application No. 2917545) filed 09 July 
2014, HHS Reference No.: E-482-2013/0-CA-03
4. European Patent Application (Application No. 14745037.3) filed 09 
July 2014, HHS Reference No.: E-482-2013/0-EP-04
5. U.S. Patent Application (Allowed Application No. 14/904,385) 
filed January 11, 2016, HHS Reference No.: E-482-2013/0-US-05

    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be where patent 
applications are filed and the field of use may be limited to 
``Photoactivatable liposomal nanoparticle for the delivery of an 
immunotherapeutic or immunotherapeutic-enabling agent''. Additional 
licensable fields of use are available (e.g. encapsulating imaging 
agent).
    This technology discloses a photoactivatable, lipid-based 
nanoparticles containing at least one hydrophilic agent, wherein the 
agent could be an anti-cancer agent, an imaging agent, or an anti-
inflammatory agent and the lipid bilayer wall of the nanoparticle is 
comprised of (i) a lipid bilayer comprising (a) 1,2-bis(tricosa-10,12-
diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), (b) 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-methoxy(polyethylene glycol) (DSPE-PEG) 
and (c) dipalmitoylphosphatidylcholine (DPPC), and (ii) a tetrapyrollic 
photosensitizer, 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a 
(HPPH), and wherein the encapsulated agent is released by exposure to 
near-infrared light.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.

[[Page 45948]]

    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: August 31, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2018-19604 Filed 9-10-18; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>